{"id":42082,"date":"2025-09-23T15:06:01","date_gmt":"2025-09-23T07:06:01","guid":{"rendered":"https:\/\/flcube.com\/?p=42082"},"modified":"2025-09-23T15:06:01","modified_gmt":"2025-09-23T07:06:01","slug":"huadong-medicine-secures-fda-ind-approval-for-hdm2017-adc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42082","title":{"rendered":"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel antibody\u2011drug conjugate <strong>HDM2017 Injection<\/strong>. The decision allows the company to initiate a Phase\u202f1 clinical trial to evaluate HDM2017 in patients with advanced malignant solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-hdm2017\">What Is HDM2017?<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted ADC<\/strong> \u2013 HDM2017 is the first antibody\u2011drug conjugate (ADC) designed to bind <strong>Cadherin\u201117 (CDH17)<\/strong>, a cell\u2011surface protein overexpressed in a range of solid tumors.<\/li>\n\n\n\n<li><strong>Composition<\/strong> \u2013 The conjugate couples an anti\u2011CDH17 monoclonal antibody to a topoisomerase\u2011I inhibitor via a cleavable linker, achieving a drug\u2011to\u2011antibody ratio (DAR) of\u202f4.<\/li>\n\n\n\n<li><strong>Preclinical Profile<\/strong> \u2013 In vitro and in vivo studies demonstrate favorable druggability, robust safety margins, and potent antitumor activity against CDH17\u2011positive colorectal, pancreatic, and gastric cancer models.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-ind-approval\">FDA IND Approval<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Milestone<\/strong> \u2013 The IND clearance confirms that the FDA considers the preclinical data sufficient to warrant human testing, marking a critical step toward clinical development.<\/li>\n\n\n\n<li><strong>Phase\u202f1 Trial Design<\/strong> \u2013 The first\u2011in\u2011human study will enroll patients with advanced, refractory solid tumors, evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy of HDM2017.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Advantage<\/strong> \u2013 As the only CDH17\u2011targeted ADC in the pipeline, HDM2017 positions Huadong Medicine at the forefront of precision oncology.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong> \u2013 FDA approval provides a launchpad for international collaboration and potential commercialization beyond China\u2019s domestic market.<\/li>\n\n\n\n<li><strong>Portfolio Growth<\/strong> \u2013 Success of HDM2017 could accelerate Huadong\u2019s broader ADC development agenda, reinforcing its reputation as a leader in targeted cancer therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42083,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,114,887],"class_list":["post-42082","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-huadong-medicine","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine Secures FDA IND Approval for HDM2017 ADC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel antibody\u2011drug conjugate HDM2017 Injection. The decision allows the company to initiate a Phase\u202f1 clinical trial to evaluate HDM2017 in patients with advanced malignant solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42082\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel antibody\u2011drug conjugate HDM2017 Injection. The decision allows the company to initiate a Phase\u202f1 clinical trial to evaluate HDM2017 in patients with advanced malignant solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42082\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T07:06:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2305.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC\",\"datePublished\":\"2025-09-23T07:06:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2305.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"Huadong Medicine\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42082#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42082\",\"name\":\"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2305.webp\",\"datePublished\":\"2025-09-23T07:06:01+00:00\",\"description\":\"Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel antibody\u2011drug conjugate HDM2017 Injection. The decision allows the company to initiate a Phase\u202f1 clinical trial to evaluate HDM2017 in patients with advanced malignant solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42082\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2305.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2305.webp\",\"width\":1080,\"height\":608,\"caption\":\"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42082#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel antibody\u2011drug conjugate HDM2017 Injection. The decision allows the company to initiate a Phase\u202f1 clinical trial to evaluate HDM2017 in patients with advanced malignant solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42082","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC","og_description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel antibody\u2011drug conjugate HDM2017 Injection. The decision allows the company to initiate a Phase\u202f1 clinical trial to evaluate HDM2017 in patients with advanced malignant solid tumors.","og_url":"https:\/\/flcube.com\/?p=42082","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-23T07:06:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2305.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42082#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42082"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC","datePublished":"2025-09-23T07:06:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42082"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42082#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2305.webp","keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","Huadong Medicine","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42082#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42082","url":"https:\/\/flcube.com\/?p=42082","name":"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42082#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42082#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2305.webp","datePublished":"2025-09-23T07:06:01+00:00","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel antibody\u2011drug conjugate HDM2017 Injection. The decision allows the company to initiate a Phase\u202f1 clinical trial to evaluate HDM2017 in patients with advanced malignant solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42082#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42082"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42082#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2305.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2305.webp","width":1080,"height":608,"caption":"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42082#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine Secures FDA IND Approval for HDM2017 ADC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2305.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42082"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42082\/revisions"}],"predecessor-version":[{"id":42084,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42082\/revisions\/42084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42083"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}